The overall aim in Part 1 is to compare the pharmacokinetic (PK)/pharmacodynamics (PD)
relationship in intravenous (IV) versus subcutaneous (SQ) terbutaline sulfate to identify the
optimal IV dosing range for use in Part 2.
The overall aim in Part 2 is to evaluate the optimal IV dosing of terbutaline sulfate based
on PD response and safety data.